Abstract
Apoptosis-inducing Fas ligand (FasL) is a type II membrane protein, predominantly expressed in the activated T cells. FasL is cleaved by a putative metalloproteinase to produce a soluble form. Here, we blocked the shedding of human FasL by deleting its cleavage site. Although human Jurkat cells and mouse primary hepatocytes that express a low level of Fas were resistant to the soluble form of FasL, they were efficiently killed by membrane-bound FasL. Furthermore, soluble FasL inhibited cytotoxicity of the membrane-bound FasL. These results indicate that the membrane-bound form of FasL is the functional form and suggest that shedding of FasL is to prevent the killing of the healthy bystander cells by cytotoxic T cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nagata, S. Apoptosis by death factor. Cell 88, 355–365 (1997).
Tanaka, M., Suda, T., Takahashi, T. & Nagata, S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14, 1129–1135 (1995).
Perez, C. et al. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63, 251–258 (1990).
Pietravalle, F. et al. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J. Biol. Chem. 271, 5965–5967 (1996).
Tanaka, M. et al. Fas ligand in human serum. Nature Med. 2, 317–322 (1996).
Gearing, A.J. et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370, 555–557 (1994).
McGeehan, G.M. et al. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 370, 558–561 (1994).
Mohler, K.M. et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370, 218–220 (1994).
Black, R.A. et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385, 729–733 (1997).
Moss, M.L. et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour necrosis factor-α. Nature 385, 733–736 (1997).
Nagata, S. & Golstein, P. The Fas death factor. Science 267, 1449–1456 (1995).
Arase, H., Arase, N. & Saito, T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. 181, 1235–1238 (1995).
Rouvier, E., Luciani, M.-F. & Golstein, P. Fas involvement in Ca2+-independent T cell-mediated cytotoxicity. J. Exp. Med. 177, 195–200 (1993).
French, L.E. et al. Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 133, 335–343 (1996).
Leithauser, F. et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplas-tic cells. Lab. Invest. 69, 415–429 (1993).
Watanabe-Fukunaga, R. et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148, 1274–1279 (1992).
Suda, T. et al. Expression of the Fas ligand in cells of T-cell-lineage. J. Immunol. 154, 3806–3813 (1995).
Lowin, B., Hahne, M., Mattmann, C. & Tschopp, J. cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370, 650–652 (1994).
Kägi, D. et al. Fas and perforin pathway as major mechanisms of T cell-mediated cytotoxicity. Science 265, 528–530 (1994).
Kondo, T., Suda, T., Fukuyama, H., Adachi, M. & Nagata, S. Essential roles of the Fas ligand in the development of hepatitis. Nature Med. 3, 409–413 (1997).
Chrvonsky, A.V. et al. The role of Fas in autoimmune diabetes. Cell 89, 17–24 (1997).
Giordano, C. et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275, 960–963 (1997).
Itoh, N. et al. Requirement of Fas for the development of autoimmune diabetes in non-obese diabetic mice. J. Exp. Med. 186, 613–618 (1997).
Tanaka, M., Suda, T., Yatomi, T., Nakamura, N. & Nagata, S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J. Immunol. 158, 2303–2309 (1997).
Takahashi, S. et al. Establishment of apoptosis-inducing monoclonal antibody 2D1 and 2D1 -resistant variants of human T cell lines. Eur. J. Immunol. 23, 1935–1941 (1993).
Ni, R. et al. Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp. Cell Res. 215, 332–337 (1994).
Takahashi, T. et al. Human Fas ligand; gene structure, chromosomal location and species specificity. Int. Immunol. 6, 1567–1574 (1994).
Aggarwal, B.B. et al. Human tumor necrosis factor: Production, purification, and characterization. J. Biol. Chem. 260, 2345–2354 (1985).
Graf, D. et al. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur. J. Immunol. 25, 1749–1754 (1995).
Wolfsberg, T.G. et al. ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev. Biol. 169, 378–383 (1995).
Yagami, H.T. et al. A metalloprotease-disintegrin participating in myoblast fusion. Nature 377, 652–6 (1995).
Pietravalle, F. et al. Cleavage of membrane-bound CD40 ligand is not required for inducing B cell proliferation and differentiation. Eur. J. Immunol. 26, 725–728 (1996).
Kischkel, F.C. et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins from a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579–5588 (1995).
Watanabe, N. et al. Continuous internalization of tumor necrosis factor receptors in a human myosarcoma cell line. J. Biol. Chem. 263, 10262–10266 (1988).
Medema, J.P. et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16, 2794–2804 (1997).
Grell, M. et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 793–802 (1995).
Solorzano, C.C. et al. Involvement of 26-kDa cell-associated TNF-alpha in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J. Immunol. 158, 414–419 (1997).
Bellgrau, D. et al. A role for CD95 ligand in preventing graft rejection. Nature 377, 630–632 (1995).
Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R. & Ferguson, T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189–1192 (1995).
Lau, H.T., Yu, M., Fontana, A. & Stoeckert, C.J., jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273, 109–112 (1996).
Allison, J., Georgiou, H.M., Strasser, A. & Vaux, D.L. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94, 3943–3947 (1997).
Seino, K., Kayagaki, N., Okumura, K. & Yagita, H. Antitumor effect of locally produced CD95 ligand. Nature Med. 3, 165–170 (1997).
Kang, S.M. et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 3, 738–743 (1997).
Karp, S.E. et al. In vivo activity of tumor necrosis factor (TNF) mutants: Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor. J. Immunol. 149, 2076–2081 (1992).
Mizushima, S. & Nagata, S. pEF-BOS: A powerful mammalian expression vector. Nucleic Acids Res. 18, 5322 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tanaka, M., Itai, T., Adachi, M. et al. Downregulation of Fas ligand by shedding. Nat Med 4, 31–36 (1998). https://doi.org/10.1038/nm0198-031
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0198-031
This article is cited by
-
T cell apoptosis characterizes severe Covid-19 disease
Cell Death & Differentiation (2022)
-
A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Journal of Neuroinflammation (2019)
-
The promise and challenges of immune agonist antibody development in cancer
Nature Reviews Drug Discovery (2018)
-
Inflammatory and Fibrinolytic System in Acute Respiratory Distress Syndrome
Lung (2018)
-
Activated Stat5 trafficking Via Endothelial Cell-derived Extracellular Vesicles Controls IL-3 Pro-angiogenic Paracrine Action
Scientific Reports (2016)